Bristol-Myers Squibb's top products based on revenue 2022-2024
Published by
Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. In 2024, their top products included Revlimid and Opdivo, drugs used in the treatment of certain cancers, and Eliquis, an anticoagulant. Those drugs generated 5.8, 9.3, and 13.3 billion U.S. dollars in revenue for the company, respectively. Other top drugs for the company included Orencia, Sprycel and Yervoy, to name a few. BMS announced in April 2019 and completed in November 2019 the acquisition of Celgene, thus making one of the largest pharma mega deals in the last years.
Bristol-Myers Squibb’s company profile
Bristol-Myers Squibb (BMS) is a pharmaceutical company that produces pharmaceuticals and biologics in several therapeutic areas. BMS has experienced increasing revenues, especially among their prioritized brand areas. Despite increasing revenues, the company’s net income has remained variable over time.
The global oncology market
The global oncology market has grown significantly recently, with new therapies being added every year. Bristol-Myers Squibb (BMS) is ranked among the very top pharmaceutical companies based on their global oncology market share. Other leading pharmaceutical companies include Roche and Johnson & Johnson. The top oncology products worldwide based on revenue include Keytruda, Revlimid, and Imbruvica, which are marketed by Merck, BMS, and J&J/AbbVie, respectively.
